|
1
|
Akalin S, Berntorp K, Ceriello A, Das AK,
Kilpatrick ES, Koblik T, Munichoodappa CS, Pan CY, Rosenthall W,
Shestakova M, et al: Intensive glucose therapy and clinical
implications of recent data: A consensus statement from the global
task force on glycaemic control. Int J Clin Pract. 63:1421–1425.
2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Preis SR, Pencina MJ, Hwang SJ, D'Agostino
RB Sr, Savage PJ, Levy D and Fox CS: Trends in cardiovascular
disease risk factors in individuals with and without diabetes
mellitus in the Framingham heart study. Circulation. 120:212–220.
2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Castro-Correia C, Maia ML, Norberto S,
Costa-Santos C, Barroso MF, Carvalho A, Fontoura M, Domingues V and
Calhau C: Can antioxidative status be involved in type 1 diabetes?
J Clin Med Res. 9:998–1001. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
McCarthy O, Moser O, Eckstein ML, Bain SC,
Pitt J and Bracken R: Supplementary nitric oxide donors and
exercise as potential means to improve vascular health in people
with type 1 diabetes: Yes to no? Nutrients. 11(1571)2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Giugliano D, Ceriello A and Paolisso G:
Diabetes mellitus, hypertension, and cardiovascular disease: Which
role for oxidative stress? Metabolism. 44:363–368. 1995.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Evans JL, Goldfine ID, Maddux BA and
Grodsky GM: Are oxidative stress-activated signaling pathways
mediators of insulin resistance and beta-cell dysfunction?
Diabetes. 52:1–8. 2003.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Gori T and Münzel T: Oxidative stress and
endothelial dysfunction: Therapeutic implications. Ann Med.
43:259–272. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kurosaki Y, Imoto A, Kawakami F, Yokoba M,
Takenaka T, Ichikawa T, Katagiri M and Ishii N: Oxidative stress
increases megalin expression in the renal proximal tubules during
the normoalbuminuric stage of diabetes mellitus. Am J Physiol Renal
Physiol. 314:F462–F470. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Salisbury D and Bronas U: Reactive oxygen
and nitrogen species: Impact on endothelial dysfunction. Nurs Res.
64:53–66. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sáez T, Salsoso R, Leiva A, Toledo F, de
Vos P, Faas M and Sobrevia L: Human umbilical vein
endothelium-derived exosomes play a role in foetoplacental
endothelial dysfunction in gestational diabetes mellitus. Biochim
Biophys Acta Mol Basis Dis. 1864:499–508. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ambasta RK, Kohli H and Kumar P: Multiple
therapeutic effect of endothelial progenitor cell regulated by
drugs in diabetes and diabetes related disorder. J Transl Med.
15(185)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Burtenshaw D, Hakimjavadi R, Redmond EM
and Cahill PA: Nox, reactive oxygen species and regulation of
vascular cell fate. Antioxidants (Basel). 6(90)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Dong J, Wong SL, Lau CW, Lee HK, Ng CF,
Zhang L, Yao X, Chen ZY, Vanhoutte PM and Huang Y: Calcitriol
protects renovascular function in hypertension by down-regulating
angiotensin II type 1 receptors and reducing oxidative stress. Eur
Heart J. 33:2980–2990. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Buday A, Orsy P, Godó M, Mózes M, Kökény
G, Lacza Z, Koller A, Ungvári Z, Gross ML, Benyó Z and Hamar P:
Elevated systemic TGF-beta impairs aortic vasomotor function
through activation of NADPH oxidase-driven superoxide production
and leads to hypertension, myocardial remodeling, and increased
plaque formation in apoE(-/-) mice. Am J Physiol Heart Circ
Physiol. 299:H386–H395. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang X, Zhao S, Su M, Sun L, Zhang S, Wang
D, Liu Z, Yuan Y, Liu Y and Li Y: Geraniol improves endothelial
function by inhibiting NOX-2 derived oxidative stress in high fat
diet fed mice. Biochem Biophys Res Commun. 474:182–187.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li J, Huang L, Wang S, Yao Y and Zhang Z:
Astragaloside IV attenuates inflammatory reaction via activating
immune function of regulatory T-cells inhibited by HMGB1 in mice.
Pharm Biol. 54:3217–3225. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang N, Wang XH, Mao SL and Zhao F:
Astragaloside IV improves metabolic syndrome and endothelium
dysfunction in fructose-fed rats. Molecules. 16:3896–3907.
2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Guo H, Cao A, Chu S, Wang Y, Zang Y, Mao
X, Wang H, Wang Y, Liu C, Zhang X and Peng W: Astragaloside IV
attenuates podocyte apoptosis mediated by endoplasmic reticulum
stress through upregulating sarco/endoplasmic reticulum
Ca2+-ATPase 2 expression in diabetic nephropathy. Front
Pharmacol. 7(500)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang L, Chi YF, Yuan ZT, Zhou WC, Yin PH,
Zhang XM, Peng W and Cai H: Astragaloside IV inhibits renal
tubulointerstitial fibrosis by blocking TGF-β/Smad signaling
pathway in vivo and in vitro. Exp Biol Med (Maywood).
239:1310–1324. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Motomura K, Fujiwara Y, Kiyota N,
Tsurushima K, Takeya M, Nohara T, Nagai R and Ikeda T:
Astragalosides isolated from the root of astragalus radix inhibit
the formation of advanced glycation end products. J Agric Food
Chem. 57:7666–7672. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Guo H, Wang Y, Zhang X, Zang Y, Zhang Y,
Wang L, Wang H, Wang Y, Cao A and Peng W: Astragaloside IV protects
against podocyte injury via SERCA2-dependent ER stress reduction
and AMPKα-regulated autophagy induction in streptozotocin-induced
diabetic nephropathy. Sci Rep. 7(6852)2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Qiao Y, Fan CL and Tang MK: Astragaloside
IV protects rat retinal capillary endothelial cells against high
glucose-induced oxidative injury. Drug Des Devel Ther.
11:3567–3577. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang N, Siu F and Zhang Y: Effect of
astragaloside IV on diabetic gastric mucosa in vivo and in vitro.
Am J Transl Res. 9:4902–4913. 2017.PubMed/NCBI
|
|
24
|
Yu WN, Sun LF and Yang H: Inhibitory
effects of astragaloside IV on bleomycin-induced pulmonary fibrosis
in rats via attenuation of oxidative stress and inflammation.
Inflammation. 39:1835–1841. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sun J, Chen XL, Zheng JY, Zhou JW and Ma
ZL: Astragaloside IV protects new born rats from anesthesia-induced
apoptosis in the developing brain. Exp Ther Med. 12:1829–1835.
2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gu DM, Lu PH, Zhang K, Wang X, Sun M, Chen
GQ and Wang Q: EGFR mediates astragaloside IV-induced Nrf2
activation to protect cortical neurons against in vitro
ischemia/reperfusion damages. Biochem Biophys Res Commun.
457:391–397. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Reagan-Shaw S, Nihal M and Ahmad N: Dose
translation from animal to human studies revisited. FASEB J.
22:659–661. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chu S, Wang L, Mao XD and Peng W:
Improvement of huangqi decoction on endothelial dysfunction in 5/6
nephrectomized rats. Cell Physiol Biochem. 40:1354–1366.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kawano N, Emoto M, Mori K, Yamazaki Y,
Urata H, Tsuchikura S, Motoyama K, Morioka T, Fukumoto S, Shoji T,
et al: Association of endothelial and vascular smooth muscle
dysfunction with cardiovascular risk factors, vascular
complications, and subclinical carotid atherosclerosis in type 2
diabetic patients. J Atheroscler Thromb. 19:276–284.
2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Islam MZ, Van Dao C, Miyamoto A and
Shiraishi M: Rho-kinase and the nitric oxide pathway modulate
basilar arterial reactivity to acetylcholine and angiotensin II in
streptozotocin-induced diabetic mice. Naunyn Schmiedebergs Arch
Pharmacol. 390:929–938. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Guo Z, Zhang Y, Liu C, Youn JY and Cai HL:
Toll-like Receptor 2 (TLR2) deficiency abrogates diabetic and obese
phenotypes while restoring endothelial function via inhibition of
NOX1. Diabetes: Jun 14, 2021 (Epub ahead of print). doi:
10.2337/db20-0591.
|
|
32
|
Varghese JF, Patel R and Yadav UCS: Novel
insights in the metabolic syndrome-induced oxidative stress and
inflammation-mediated atherosclerosis. Curr Cardiol Rev. 14:4–14.
2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Versari D, Daghini E, Virdis A, Ghiadoni L
and Taddei S: Endothelial dysfunction as a target for prevention of
cardiovascular disease. Diabetes Care. 32 (Suppl 2):S314–S321.
2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tangvarasittichai S: Oxidative stress,
insulin resistance, dyslipidemia and type 2 diabetes mellitus.
World J Diabetes. 6:456–480. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Cicek FA, Kandilci HB and Turan B: Role of
ROCK upregulation in endothelial and smooth muscle vascular
functions in diabetic rat aorta. Cardiovasc Diabetol.
12(51)2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Schwendemann J, Sehringer B, Noethling C,
Zahradnik HP and Schaefer WR: Nitric oxide detection by DAF
(diaminofluorescein) fluorescence in human myometrial tissue.
Gynecol Endocrinol. 24:306–311. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Planchet E and Kaiser WM: Nitric oxide
(NO) detection by DAF fluorescence and chemiluminescence: A
comparison using abiotic and biotic NO sources. J Exp Bot.
57:3043–3055. 2006.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Van Hove CE, Van der Donckt C, Herman AG,
Bult H and Fransen P: Vasodilator efficacy of nitric oxide depends
on mechanisms of intracellular calcium mobilization in mouse aortic
smooth muscle cells. Br J Pharmacol. 158:920–930. 2009.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Cao W, Cui J, Li S, Zhang D, Guo Y, Li Q,
Luan Y and Liu X: Crocetin restores diabetic endothelial progenitor
cell dysfunction by enhancing NO bioavailability via regulation of
PI3K/AKT-eNOS and ROS pathways. Life Sci. 181:9–16. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Magenta A, Greco S, Capogrossi MC, Gaetano
C and Martelli F: Nitric oxide, oxidative stress, and p66Shc
interplay in diabetic endothelial dysfunction. Biomed Res Int.
2014(193095)2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Förstermann U, Xia N and Li H: Roles of
vascular oxidative stress and nitric oxide in the pathogenesis of
atherosclerosis. Circ Res. 120:713–735. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ding X, Zhang M, Gu R, Xu G and Wu H:
Activated microglia induce the production of reactive oxygen
species and promote apoptosis of co-cultured retinal microvascular
pericytes. Graefes Arch Clin Exp Ophthalmol. 255:777–788.
2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Thum T, Fraccarollo D, Schultheiss M,
Froese S, Galuppo P, Widder JD, Tsikas D, Ertl G and Bauersachs J:
Endothelial nitric oxide synthase uncoupling impairs endothelial
progenitor cell mobilization and function in diabetes. Diabetes.
56:666–674. 2007.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Hohenstein B, Hugo CP, Hausknecht B,
Boehmer KP, Riess RH and Schmieder RE: Analysis of NO-synthase
expression and clinical risk factors in human diabetic nephropathy.
Nephrol Dial Transplant. 23:1346–1354. 2008.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhang BQ, Hu SJ, Qiu LH, Zhu JH, Xie XJ,
Sun J, Zhu ZH, Xia Q and Bian K: Effects of Astragalus
membranaceus and its main components on the acute phase
endothelial dysfunction induced by homocysteine. Vascul Pharmacol.
46:278–285. 2007.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Holterman CE, Read NC and Kennedy CR: Nox
and renal disease. Clin Sci (Lond). 128:465–481. 2015.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Tian R, Ding Y, Peng YY and Lu N:
Myeloperoxidase amplified high glucose-induced endothelial
dysfunction in vasculature: Role of NADPH oxidase and hypochlorous
acid. Biochem Biophys Res Commun. 484:572–578. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Drummond GR, Selemidis S, Griendling KK
and Sobey CG: Combating oxidative stress in vascular disease: NADPH
oxidases as therapeutic targets. Nat Rev Drug Discov. 10:453–471.
2011.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Konior A, Schramm A, Czesnikiewicz-Guzik M
and Guzik TJ: NADPH oxidases in vascular pathology. Antioxid Redox
Signal. 20:2794–2814. 2014.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Zhao QD, Viswanadhapalli S, Williams P,
Shi Q, Tan C, Yi X, Bhandari B and Abboud HE: NADPH oxidase 4
induces cardiac fibrosis and hypertrophy through activating
Akt/mTOR and NFκB signaling pathways. Circulation. 131:643–655.
2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Lee HY, Zeeshan HMA, Kim HR and Chae HJ:
Nox4 regulates the eNOS uncoupling process in aging endothelial
cells. Free Radic Biol Med. 113:26–35. 2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Murdoch CE, Alom-Ruiz SP, Wang M, Zhang M,
Walker S, Yu B, Brewer A and Shah AM: Role of endothelial Nox2
NADPH oxidase in angiotensin II-induced hypertension and vasomotor
dysfunction. Basic Res Cardiol. 106:527–538. 2011.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Rezende F, Moll F, Walter M, Helfinger V,
Hahner F, Janetzko P, Ringel C, Weigert A, Fleming I, Weissmann N,
et al: The NADPH organizers NoxO1 and p47phox are both mediators of
diabetes-induced vascular dysfunction in mice. Redox Biol.
15:12–21. 2018.PubMed/NCBI View Article : Google Scholar
|
